This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Absence status epilepticusAbsence Status Epilepticus (Petit Mal Status Epilepticus)

Contents — quick navigation
ABasic informationICD-10: G41.1 | Special Copayment Reduction: V125 | Coverage period: 5 years
BSynonymsPetit mal status epilepticus, absence status epilepticus (ASE), spike-wave stupor, epileptic twilight state
CAdult onsetCan occur in both children and adults; when newly occurring in adults, differentiation from LGS, absence epilepsy in the elderly, etc. is needed
S1HistoryFrom 19th-century "vague epilepsy" to the establishment of the ASE concept
S2CausesWorsening of childhood absence epilepsy, inappropriate antiseizure medication, metabolic abnormalities, drug toxicity
S3GeneticsAbsence epilepsy-related genes such as GABRG2, GABRA1, and CACNA1A
S4General epidemiologyAbout 25% of nonconvulsive SE; occurs in some patients with childhood absence epilepsy
S5PathophysiologySustained 3 Hz synchronization of the cortico-thalamic circuit; GABA-B receptor-mediated
S6SymptomsClouding of consciousness, reduced responsiveness, and behavioral changes lasting minutes to days; no convulsions
S7SignsSustained 3 Hz spike-and-slow-wave on EEG; eyelid fluttering, automatisms; clinically subtle
S8ScreeningEEG (immediately); blood levels of antiseizure medications; metabolic panel
S9DiagnosisEEG essential for diagnosis; Salzburg criteria; differentiate from tonic-clonic SE and CPSE
S10TreatmentIntravenous or intranasal benzodiazepines; valproic acid; add ethosuximide
S11PrognosisMostly good; complete recovery with early treatment; preventing recurrence is important
S12PreventionMaintain optimal treatment of absence epilepsy; avoid seizure triggers
S13References10 key references

S1. History

Absence status epilepticus (ASE) has been described since the 19th century under various names such as "vague epilepsy", "masked epilepsy", and "epileptic stupor". In 1876, Gowers described epileptic episodes with clouding of consciousness, and in 1956 Lennox named this "petit mal status".

The modern concept of ASE was established along with advances in EEG technology, based on the cortico-thalamic circuit theory of Penfield and Jasper in 1965. Gastaut (1967) defined ASE as a status state of the typical absence epilepsy syndrome, and a classification system subsequently formed that distinguishes typical ASE (occurring in typical absence epilepsy) from atypical ASE (occurring in LGS and other epilepsy syndromes).

In 1998, Shorvon used the term "spike-wave stupor" to emphasize the association between sustained spike-and-slow-wave on EEG and clinical clouding of consciousness. At the 2013 Salzburg consensus meeting, standardized EEG diagnostic criteria for nonconvulsive SE were presented, and ASE was clearly defined within these criteria. In the 2015 ILAE classification, ASE was explicitly included as a type of nonconvulsive SE.

Historically, because of its lack of convulsions, ASE was often mistaken for a psychiatric condition, metabolic encephalopathy, or simple behavioral change, which caused delays in diagnosis and treatment. With advances in modern EEG monitoring technology, the recognition rate of ASE has improved greatly.

S2. Causes

The causes of ASE are classified according to the type of underlying epilepsy syndrome and triggering factors.

Causes of typical ASE

Triggering factors

Causes of atypical ASE

S3. Genetics

Typical absence epilepsy and related ASE have a strong genetic predisposition. The concordance rate of childhood absence epilepsy is high in monozygotic twins, at about 75–85%.

Major associated genes

GeneEncoded proteinAssociated syndromes
GABRG2GABA-A receptor γ2 subunitChildhood absence epilepsy, febrile seizures
GABRA1GABA-A receptor α1 subunitChildhood absence epilepsy
CACNA1AP/Q-type voltage-dependent Ca2+ channelChildhood absence epilepsy, ataxia
CACNA1HT-type voltage-dependent Ca2+ channelChildhood absence epilepsy
CLCN2ClC-2 chloride channelJuvenile myoclonic epilepsy, absence epilepsy
SLC2A1GLUT1 glucose transporterAbsence-like seizures associated with GLUT1 deficiency

Childhood absence epilepsy arises from polygenic inheritance, with multiple genes and environmental factors interacting. A specific GABRG2 mutation (e.g., R43Q) is associated with familial occurrence of absence epilepsy and febrile seizures. Genetic testing is not routinely needed in typical childhood absence epilepsy but is considered when there are atypical features or a family history.

S4. General epidemiology

ASE is the most easily recognized type of nonconvulsive SE (NCSE), but because its clinical warning signs are subtle, diagnostic delay is still common. Nonconvulsive SE accounts for about 25–40% of all SE patients, of which ASE is estimated at about 25–30%.

The incidence of ASE in patients with childhood absence epilepsy is reported to be about 10–15%. Typical ASE occurs mainly in childhood and adolescence, but it can also occur in adults, in which case identifying the cause is more important. ASE first occurring in adulthood is more often symptomatic (with an identifiable cause) than idiopathic.

Compared with convulsive SE, ASE has lower mortality and rare neurological sequelae, so its prognosis is relatively good. However, there are reports that it may affect cognitive function when it persists for a long time (hours to days). The longer the diagnostic delay, the more it can lead to unnecessary tests, mistreatment, and increased medical costs.

S5. Pathophysiology

The pathophysiology of ASE is explained by abnormal, sustained oscillation of the cortico-thalamic circuit.

Sustained synchronization of the cortico-thalamic circuit

In a normal absence seizure, 3 Hz oscillation in the cortico-thalamic loop occurs for a few seconds and then terminates spontaneously. In ASE, this oscillation does not terminate and persists; proposed mechanisms include hyperactivation of GABA-B receptors in the thalamic reticular nucleus (TRN), sustained activation of low-threshold T-type calcium channels, and an abnormal increase in cortical excitability.

Role of GABA-B receptors

The fact that GABA-B receptor agonists (baclofen) can induce or worsen absence seizures suggests that rebound de-inhibition after GABA-B-mediated inhibition contributes to seizure generation. Because GABA-A receptor-mediated inhibition plays a key role in ASE, benzodiazepines are effective treatments.

T-type calcium channels

Low-threshold T-type voltage-dependent calcium channels (Cav3.1, Cav3.2) in thalamic neurons enable burst firing of thalamic neurons, which forms the basis of cortico-thalamic synchronization. Ethosuximide suppresses absence seizures and ASE by blocking T-type calcium channels.

S6. Symptoms

ASE is a state of clouded consciousness without convulsions that lasts from minutes to days. Because its clinical presentation is subtle, it is often mistaken for a psychiatric condition or metabolic encephalopathy.

Main clinical symptoms

Duration

Typical ASE lasts from minutes to hours, but cases lasting several days are not uncommonly reported. In particular, "de novo ASE" occurring in the elderly involves a state of cognitive impairment lasting several days and is easily mistaken for dementia or a psychiatric condition.

S7. Signs

EEG findings

ASE cannot be diagnosed without EEG. Characteristic EEG findings are as follows.

Physical examination findings

There are no convulsions, and reflexes and muscle tone are generally preserved. Pupillary responses and deep tendon reflexes are often normal. The 3 Hz rhythm of eyelid blinking is a clinical clue that matches the EEG frequency. A sudden return to clear consciousness when the seizure ends is characteristic.

S8. Screening

Tests to screen for ASE in patients with clouded consciousness or cognitive impairment are as follows.

EEG (performed immediately)

When ASE is suspected, EEG is the most important screening tool. An emergency EEG or portable EEG is performed promptly. When reading the EEG, check whether typical 3 Hz spike-and-slow-wave persists. A hyperventilation provocation test may help diagnosis.

Blood levels of antiseizure medications

In patients with underlying absence epilepsy, checking whether blood levels of antiseizure medications (ethosuximide, valproic acid) are outside the therapeutic range is important for identifying triggers.

Metabolic panel

Metabolic triggers are excluded with blood glucose, electrolytes (Na, Ca, Mg), renal function, and liver function tests. For ASE first occurring in adults, brain MRI and autoimmune antibody (LGI1, GABA-B, etc.) testing are additionally performed.

S9. Diagnosis

ASE is diagnosed by a combination of the clinical presentation (clouding of consciousness, automatisms) and EEG (sustained 3 Hz spike-and-slow-wave). In patients without convulsions who show changes in consciousness, nonconvulsive SE must always be considered in the differential.

Applying the Salzburg criteria

According to the Salzburg EEG criteria for nonconvulsive SE (2013), the following conditions are required to diagnose ASE: epileptiform discharges with a frequency above 2.5 Hz, or, even at 2.5 Hz or below, persistent epileptiform discharges with EEG improvement and accompanying clinical improvement after administration of antiseizure medication.

Differential diagnosis

Differential diagnosisDistinguishing features from ASE
Complex partial status epilepticus (CPSE)Focal EEG seizure onset; more complex automatisms; temporal/frontal lobe origin
Postictal phase of tonic-clonic SEClear seizure history; EEG slowing (no ictal discharges); gradual recovery
Metabolic encephalopathyEEG slowing without ictal discharges; triphasic wave pattern possible
Psychiatric condition (dissociation)Normal EEG; distinguished by past history and psychiatric evaluation
Transient global amnesia (TGA)Single episode, predominantly memory impairment; no ictal discharges on EEG

S10. Treatment

ASE is not as urgent as convulsive SE, but because it can affect cognitive function when prolonged, prompt treatment is recommended.

Acute treatment

Optimizing treatment of the underlying absence epilepsy

Optimize the dose of ethosuximide (first choice for typical absence epilepsy) or valproic acid. Avoid drugs that can worsen absence seizures (carbamazepine, oxcarbazepine, phenytoin). Lamotrigine has a synergistic effect when combined with valproic acid, but when used alone it may worsen absences in some patients.

Atypical ASE (LGS-related)

Valproic acid + clobazam combination; follow the LGS treatment protocol; ethosuximide has limited efficacy for atypical absences.

S11. Prognosis

The prognosis of ASE is generally better than that of convulsive SE.

S12. Prevention

S13. References

  1. Trinka E, et al. A definition and classification of status epilepticus — Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-1523. PMID: 26336950.
  2. Shorvon S. The treatment of status epilepticus. Curr Opin Neurol. 2011;24(2):165-170. PMID: 21307770.
  3. Leitinger M, et al. Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a retrospective study. Lancet Neurol. 2016;15(10):1054-1062. PMID: 27571157.
  4. Glauser T, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010;362(9):790-799. PMID: 20200383.
  5. Tomson T, et al. Epileptic encephalopathy in absence status epilepticus. Epilepsia. 1992;33(6):967-974. PMID: 1464278.
  6. Andermann F, Robb JP. Absence status. A reappraisal following review of 38 patients. Epilepsia. 1972;13:177-187. PMID: 4624628.
  7. Drislane FW. Presentation, evaluation, and treatment of nonconvulsive status epilepticus. Epilepsy Behav. 2000;1(5):301-314. PMID: 12609144.
  8. Panayiotopoulos CP. Absence epilepsies. In: Epileptic Syndromes in Infancy, Childhood and Adolescence. 4th ed. John Libbey Eurotext; 2005.
  9. Crunelli V, Leresche N. Childhood absence epilepsy: genes, channels, neurons and networks. Nat Rev Neurosci. 2002;3(5):371-382. PMID: 11988776.
  10. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1981;22(4):489-501. PMID: 6790275.